Management of qtc Prolongation in Patients with Mutations and Evaluation of Iveocidinib

This chapter discusses the management of qtc prolongation in patients receiving iveocidinib for idH1 and Flip3 mutations, highlighting the importance of focusing on the Flip3 mutation and the impact of iveocidinib on co-occurring kinase mutations. It also explores alternative treatments and the combination of idH1 inhibitors with Flip3 inhibitors.